Nephrotic syndrome unfavorable course correlates with downregulation of podocyte vascular endothelial growth factor receptor (VEGFR)-2

Folia Histochemica et Cytobiologica

Volumn 49, Issue 3, 2011, Pages 472-478

  Ostalska Nowicka, Danuta ^a,b   Malinska, Agnieszka ^a,b   Zabel, Maciej ^a,b   Witkiewicz, Wojciech ^a   Nowicki, Michal ^a,b  

^a REGIONAL SPECIALIST HOSPITAL   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Children; Electron microscopy; Nephrotic syndrome; Vegfr 2

Indexed keywords

STEROID; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2;

ADOLESCENT; ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CHILD; CONTROLLED STUDY; CYTOPLASM; DISEASE COURSE; DOWN REGULATION; ELECTRON MICROSCOPY; FEMALE; FOCAL GLOMERULOSCLEROSIS; GENE OVEREXPRESSION; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; IMMUNOELECTRON MICROSCOPY; MAJOR CLINICAL STUDY; MALE; MINIMAL CHANGE GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PODOCYTE; PRESCHOOL CHILD; PROGNOSIS; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEIN EXPRESSION; PROTEINURIA; SCHOOL CHILD; SIGNAL TRANSDUCTION;

EID: 84856786346     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2011.0067     Document Type: Article

References (29)

1. Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol. 2009;21:154-165.
2. Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res. 2005;65:550-563.
3. Tammela T, Zarkada G, Wallgard E et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature. 2008;454:656-660.
4. Nowicki M, Ostalska-Nowicka D, Kaczmarek E, Miskowiak B, Witt M. Vascular endothelial growth factor C - a potent risk factor in childhood acute lymphoblastic leukaemia: an immunocytochemical approach. Histopathology. 2006;49: 170-177.
5. Chien MH, Ku CC, Johansson G et al. Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway. Carcinogenesis. 2009;30:2005-2013.
6. Le Bras B, Barallobre MJ, Homman-Ludiye J et al. VEGF-C is a trophic factor for neural progenitors in the vertebrate embryonic brain. Nat Neurosci. 2006;9:340-348.
7. Ostalska-Nowicka D, Zachwieja J, Nowicki M, Kaczmarek E, Siwinska A, Witt M. Vascular endothelial growth factor (VEGF-C1)-dependent inflammatory response of podocytes in nephrotic syndrome glomerulopathies in children: an immunohistochemical approach. Histopathology. 2005;46:176-183.
8. Shenoy M, Plant ND, Lewis MA, Bradbury MG, Lennon R, Webb NJ. Intravenous methylprednisolone in idiopathic childhood nephrotic syndrome. Pediatr Nephrol. 2010;25:899-903.
9. Vannay A, Fekete A, Langer R et al. Dehydroepiandrosterone pretreatment alters the ischaemia/reperfusion-induced VEGF, IL-1 and IL-6 gene expression in acute renal failure. Kidney Blood Press Res. 2009;32:175-184.
10. Foster RR, Satchell SC, Seckley J et al. VEGF-C promotes survival in podocytes. Am J Physiol Renal Physiol. 2006; 291:F196-F207.
11. Churg J, Habib R, White RH. Pathology of the nephrotic syndrome in children: a report for the International Study of Kidney Disease in Children. Lancet. 1970;760:1299-1302.
12. Ostalska-Nowicka D, Zachwieja J, Nowicki M, Kaczmarek E, Witt M. Is mesangial hypercellularity with glomerular immaturity a variant of glomerulosclerosis? Pediatr Nephrol. 2007;22:674-683.
13. Benz K, Buttner M, Dittrich K, Campean V, Dotsch J, Amann K. Characterisation of renal immune cell infiltrates in children with nephrotic syndrome. Pediatr Nephrol. 2010; 25: 1291-1298.
14. Habib R, Girardin E, Gagnadoux MF, Hinglais N, Levy M, Broyer M. Immunopathological findings in idiopathic nephrosis: clinical significance of glomerular "immune deposits''. Pediatr Nephrol. 1988;2:402-408.
15. Nowicki M, Konwerska A, Ostalska-Nowicka D et al. Vascular endothelial growth factor (VEGF)-C - a potent risk factor in children diagnosed with stadium 4 neuroblastoma. Folia Histochem Cytobiol. 2008;46:493-499.
16. Foster RR, Slater SC, Seckley J et al. Vascular endothelial growth factor-C, a potential paracrine regulator of glomerular permeability, increases glomerular endothelial cell monolayer integrity and intracellular calcium. Am J Pathol. 2008;173:938-948.
17. Timoshenko AV, Rastogi S, Lala PK. Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells. Br J Cancer. 2007;97:1090-1098.
18. Becker J, Pavlakovic H, Ludewig F et al. Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2. Clin Cancer Res. 2010;16:1431-1441.
19. You WK, Kasman I, Hu-Lowe DD, McDonald DM. Ricinus communis agglutinin I leads to rapid down-regulation of VEGFR-2 and endothelial cell apoptosis in tumor blood vessels. Am J Pathol. 2010;176:1927-1940.
20. Pourgholami MH, Khachigian LM, Fahmy RG et al. Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis. Biochem Biophys Res Commun. 2010;397:729-734.
21. Kukk E, Lymboussaki A, Taira S et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development. 1996; 122:3829-3837.
22. Karkkainen MJ, Haiko P, Sainio K et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol. 2004;5:74-80.
23. Achen MG, Jeltsch M, Kukk E et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA. 1998;95:548-553.
24. Joukov V, Sorsa T, Kumar V et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. Embo J. 1997;16:3898-3911.
25. Nowicki M, Ostalska-Nowicka D, Kaczmarek M, Miskowiak B, Witt M. The significance of VEGF-C/VEGFR-2 interaction in the neovascularization and prognosis of nephroblastoma (Wilms' tumour). Histopathology. 2007;50:358-364.
26. Tokuyama W, Mikami T, Masuzawa M, Okayasu I. Autocrine and paracrine roles of VEGF/VEGFR-2 and VEGF-C/VEGFR- 3 signaling in angiosarcomas of the scalp and face. Hum Pathol. 2010;41:407-414.
27. Kajiya K, Sawane M, Huggenberger R, Detmar M. Activation of the VEGFR-3 pathway by VEGF-C attenuates UVB-induced edema formation and skin inflammation by promoting lymphangiogenesis. J Invest Dermatol. 2009;129:1292-1298.
28. Su JL, Yen CJ, Chen PS et al. The role of the VEGF-C/VEGFR- 3 axis in cancer progression. Br J Cancer. 2007;96:541-545.
29. Urry DW, Urry KD, Szaflarski W, Nowicki M, Zabel M. Function and frustration of multi-drug ABC exporter protein and design of model proteins for drug delivery using protein hydration thermodynamics. Curr Pharm Des. 2009;15:2833-2867.